QuidelOrtho (NASDAQ:QDEL) Full Year 2024 Results

Key Financial Results

• Revenue: US$2.78b (down 7.2% from FY 2023).
• Net loss: US$2.03b (loss widened by US$2.02b from FY 2023).
• US$30.16 loss per share (further deteriorated from US$0.15 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

QuidelOrtho EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.1%.

The primary driver behind last 12 months revenue was the North America segment contributing a total revenue of US$1.62b (58% of total revenue). Notably, cost of sales worth US$1.50b amounted to 54% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling US$2.07b were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how QDEL's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.

The company's shares are down 1.1% from a week ago.

Risk Analysis

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.